Emergent BioSolutions (EBS) Reports Q3 results; updates guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.82 -1.43%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 Revenue for the quarter at $271 million versus the consensus estimate of $237.43 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1-1.1 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
